---
name: managing-aortic-disease
language: en
description: Guides aortic aneurysm and dissection evaluation with surveillance intervals and intervention thresholds. Use when monitoring aortic aneurysms, evaluating aortic dissection, or determining intervention timing.
tags:
  - management
  - cardiology
  - valuation
metadata:
  author: casemark
  practice_areas:
    - Cardiology
    - Interventional Cardiology
    - Electrophysiology
  document_types:
    - Management Report
  skill_modes:
    - Management
    - Coordination
---

# Managing Aortic Disease

Guides aortic aneurysm and dissection evaluation with surveillance intervals and intervention thresholds.

## Why This Skill Exists

Aortic disease — encompassing thoracic and abdominal aortic aneurysms, acute aortic syndromes (dissection, intramural hematoma, penetrating atherosclerotic ulcer), and genetic aortopathies — carries catastrophic mortality risk when unrecognized or inadequately managed. Acute type A aortic dissection has a 1–2% mortality rate per hour without surgery. Ruptured abdominal aortic aneurysm (AAA) carries > 80% mortality outside hospital.

The 2022 ACC/AHA Guideline for Aortic Disease provides evidence-based thresholds for surveillance imaging, surgical intervention, and medical management. Genetic aortopathies (Marfan, Loeys-Dietz, Turner, bicuspid aortic valve) have lower surgical thresholds than degenerative aneurysms. This skill ensures systematic evaluation, appropriate imaging, risk factor management, and timely referral for intervention.

---

## Checkpoint A: Pre-Draft Intake (Mandatory)

1. What is the aortic pathology — aneurysm (thoracic/abdominal), dissection, intramural hematoma, or penetrating ulcer? (default: "Pathology not specified")
2. What is the current aortic diameter at the largest segment? (default: "Diameter not documented")
3. What imaging modality was used (CT, MRI, echo, ultrasound)? (default: "Modality not specified")
4. Is the presentation acute (chest/back pain, hemodynamic instability) or chronic surveillance? (default: "Presentation type not classified")
5. Is there a history of genetic connective tissue disorder (Marfan, Loeys-Dietz, Ehlers-Danlos type IV, Turner, familial TAAD)? (default: "Genetic history not assessed")
6. Does the patient have a bicuspid aortic valve? (default: "BAV status unknown")
7. What are the current BP and antihypertensive medications? (default: "BP and medications not documented")
8. Is there a family history of aortic disease, dissection, or sudden death? (default: "Family history not obtained")

### Documents to Request

- Current aortic imaging (CT angiography, MRA, or echocardiogram)
- Prior aortic imaging for diameter trend analysis
- Genetic testing results if connective tissue disorder suspected
- Echocardiogram (aortic valve morphology, aortic root dimensions)
- Current medication list (antihypertensives, beta-blockers)
- Family history documentation (aortic disease, sudden death)
- BP records (home and office)
- Surgical history (prior aortic repair)
- Labs: BMP, CBC, type and screen (if acute)

---

## Step 1: Acute Aortic Syndrome Recognition and Classification

**Stanford Classification of Aortic Dissection:**

| Type | Involvement | Acute Management |
|------|------------|-----------------|
| Type A | Ascending aorta involved (regardless of descending) | Emergent surgical repair |
| Type B | Descending aorta only (beyond left subclavian) | Medical management; surgery for complications |

**DeBakey Classification:**
- Type I: originates in ascending, propagates to descending
- Type II: confined to ascending aorta
- Type III: originates in descending aorta

**Acute Aortic Syndromes Spectrum:**
1. Classic dissection: intimal tear with true and false lumen
2. Intramural hematoma (IMH): hemorrhage within media without intimal tear
3. Penetrating atherosclerotic ulcer (PAU): ulceration through internal elastic lamina
4. Contained aortic rupture

**Imaging for Acute Dissection:**
- CTA aorta: first-line in hemodynamically stable patients (sensitivity/specificity > 98%)
- TEE: at bedside for unstable patients or intraoperatively
- MRA: excellent but impractical in acute setting due to scan time

**Acute Type A Management:**
- Emergent surgical consultation
- IV beta-blocker first (esmolol preferred): target HR < 60, SBP 100–120
- Pain control (IV morphine/fentanyl)
- Anti-impulse therapy: reduce dP/dt (force of LV contraction)
- If BB contraindicated: nicardipine (add after HR controlled)
- Never give vasodilator without prior HR control

**Acute Uncomplicated Type B Management:**
- Medical management: IV beta-blocker → oral conversion; target SBP 100–120
- Pain control
- Serial imaging: CTA at 1 week, 1 month, 3 months, 6 months, then annually

**Complicated Type B (requiring intervention):**
- Malperfusion syndrome (mesenteric, renal, limb ischemia)
- Rupture or impending rupture
- Refractory hypertension or pain despite optimal medical therapy
- Rapid aortic expansion (> 5 mm in acute phase)
- TEVAR (thoracic endovascular aortic repair) preferred for complicated type B

---

## Step 2: Aortic Aneurysm Surveillance

**Thoracic Aortic Aneurysm (TAA) Surveillance Intervals:**

| Diameter | Interval | Notes |
|----------|----------|-------|
| < 4.0 cm | Echo every 2–3 years (if BAV or root involvement) | Baseline imaging to establish growth rate |
| 4.0–4.4 cm | Annual imaging (CT/MRI or echo) | Monitor for growth |
| 4.5–5.4 cm | Every 6–12 months (CT/MRI) | Approaching surgical threshold |
| ≥ 5.5 cm (degenerative) | Refer for surgical evaluation | At threshold |
| Growing > 0.5 cm/year | Refer for surgical evaluation | Rapid growth regardless of absolute size |

**Abdominal Aortic Aneurysm (AAA) Surveillance:**

| Diameter | Interval |
|----------|----------|
| 3.0–3.9 cm | Ultrasound every 2–3 years |
| 4.0–4.9 cm | Ultrasound every 6–12 months |
| 5.0–5.4 cm | Ultrasound or CT every 6 months |
| ≥ 5.5 cm (men) / ≥ 5.0 cm (women) | Refer for repair |
| Growing > 0.5 cm/year | Refer for repair |

**AAA Screening:** One-time ultrasound for men aged 65–75 who have ever smoked (USPSTF Grade B).

---

## Step 3: Surgical Intervention Thresholds

**TAA Repair Thresholds (ACC/AHA 2022):**

| Condition | Surgical Threshold |
|-----------|-------------------|
| Degenerative ascending aneurysm | ≥ 5.5 cm |
| Bicuspid aortic valve (BAV) | ≥ 5.0–5.5 cm (lower if risk factors) |
| Marfan syndrome | ≥ 5.0 cm (aortic root) |
| Loeys-Dietz syndrome | ≥ 4.0–4.2 cm (depending on gene mutation) |
| Turner syndrome | Aortic size index ≥ 2.5 cm/m² |
| Familial TAAD | ≥ 4.5–5.0 cm (gene-dependent) |
| Vascular Ehlers-Danlos (type IV) | Prophylactic surgery generally not recommended; celiprolol for medical management |
| Rapid growth (any etiology) | > 0.5 cm/year |
| Concomitant with other cardiac surgery | ≥ 4.5 cm (ascending) at time of AVR/CABG |

**AAA Repair Threshold:**
- ≥ 5.5 cm in men; ≥ 5.0 cm in women
- Rapid growth > 0.5 cm/year
- Symptomatic AAA regardless of size
- EVAR (endovascular) vs. open repair based on anatomy and patient fitness

---

## Step 4: Medical Management for All Aortic Disease

**Blood Pressure Control:**
- Target: SBP < 120 mmHg (strict control reduces wall stress)
- Beta-blockers: first-line (reduce HR and dP/dt)
- ARBs (losartan): first-line in Marfan syndrome (also reduces TGF-β signaling)
- ACEi: alternative to ARB
- Avoid fluoroquinolones: associated with aortic aneurysm/dissection risk

**Lifestyle Modifications:**
- Strict smoking cessation (accelerates aneurysm growth)
- Restrict heavy isometric exercise and Valsalva maneuvers (especially genetic aortopathies)
- Competitive sports restriction in Marfan and other genetic aortopathies per ACC guidelines
- Statin therapy for atherosclerotic AAA (reduces cardiovascular events, possible slowed growth)

**Genetic Evaluation:**
- Family screening echocardiogram for first-degree relatives of TAA patients
- Genetic testing for: Marfan (FBN1), Loeys-Dietz (TGFBR1/2, SMAD3, TGFB2/3), vascular EDS (COL3A1), familial TAAD (ACTA2, MYH11)
- Genetic counseling for affected families

---

## Step 5: Post-Repair Surveillance

**Post-Surgical Surveillance Schedule:**

| Procedure | Year 1 | Annual |
|-----------|--------|--------|
| Open ascending repair | CT/MRI at 1, 6, 12 months | Annual CT/MRI lifelong |
| TEVAR | CT at 1, 6, 12 months | Annual CT lifelong |
| EVAR (abdominal) | CT at 1, 6, 12 months | Annual CT (or US if no endoleak) |
| Root replacement (Bentall) | Echo at 1, 6, 12 months | Annual echo + CT/MRI every 2–3 years |

**Post-EVAR/TEVAR Endoleak Classification:**
| Type | Source | Action |
|------|--------|--------|
| I | Attachment site leak | Requires reintervention |
| II | Branch vessel backflow (lumbar, IMA) | Observe; treat if sac growth |
| III | Fabric tear or component separation | Requires reintervention |
| IV | Porosity (early, self-limited) | Observe |
| V | Endotension (sac growth without visible leak) | Close surveillance; consider conversion |

---

## Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the aortic pathology correctly classified (aneurysm, dissection, IMH, PAU)?
2. Is the aortic diameter documented with the imaging modality used?
3. Is the surgical threshold appropriate for the patient's specific etiology (genetic vs. degenerative)?
4. Is the surveillance interval correct for the current diameter?
5. Is medical management optimized (BP, beta-blocker, genetic evaluation)?

---

## Quality Audit

- [ ] Aortic pathology classified (aneurysm, dissection, IMH, PAU)
- [ ] Stanford/DeBakey classification applied for dissection
- [ ] Maximum aortic diameter documented with imaging modality and date
- [ ] Growth rate calculated from serial imaging
- [ ] Surgical threshold specific to etiology (genetic vs. degenerative)
- [ ] Beta-blocker prescribed (or contraindication documented)
- [ ] BP target < 120 mmHg systolic
- [ ] Genetic aortopathy screening performed or deferred with rationale
- [ ] Family screening recommended for first-degree relatives of TAA patients
- [ ] Lifestyle counseling documented (exercise restrictions, smoking cessation)
- [ ] Surveillance interval assigned per diameter and etiology
- [ ] Acute dissection anti-impulse therapy documented (HR < 60, SBP 100–120)
- [ ] Post-repair surveillance protocol assigned
- [ ] Endoleak classification documented for post-EVAR/TEVAR patients

---

## Guidelines

1. Acute type A aortic dissection is a surgical emergency — delay kills. Immediate surgical consultation is required upon diagnosis.
2. Always control heart rate BEFORE initiating vasodilator therapy in acute dissection — unopposed vasodilation increases aortic shear stress.
3. Genetic aortopathies have LOWER surgical thresholds than degenerative aneurysms — Loeys-Dietz may require surgery at 4.0–4.2 cm. Always assess for genetic etiology.
4. Aortic diameter must be measured consistently at the same anatomic level and using the same imaging technique across studies — variability between modalities can be 2–4 mm.
5. AAA screening (one-time ultrasound in men 65–75 who ever smoked) is a USPSTF Grade B recommendation and should be routinely offered.
6. Fluoroquinolone antibiotics should be avoided in patients with known aortic disease — FDA boxed warning for increased risk of dissection and aneurysm rupture.
7. Post-endovascular repair surveillance is lifelong — endoleak detection and sac monitoring require ongoing imaging commitment.
8. Vascular Ehlers-Danlos (type IV) is managed medically with celiprolol — prophylactic surgery carries extreme risk due to tissue fragility and is generally contraindicated.